DRI Capital offers innovative sources of royalty-based financing to inventors, institutions and life sciences companies who develop pharmaceutical products, diagnostics or medical devices. With a pool of more that more than U.S. $3 billion in capital through its third private equity fund Drug Royalty III, DRI Capital invests in carefully selected royalties on differentiated products already on the market or in the late-stages of clinical development.